Patient Blood Management in Elective Total Hip- and Knee-replacement Surgery (Part 1)

2014 ◽  
Vol 120 (4) ◽  
pp. 839-851 ◽  
Author(s):  
Cynthia So-Osman ◽  
Rob G. H. H. Nelissen ◽  
Ankie W. M. M. Koopman-van Gemert ◽  
Ewoud Kluyver ◽  
Ruud G. Pöll ◽  
...  

Abstract Background: Patient blood management combines the use of several transfusion alternatives. Integrated use of erythropoietin, cell saver, and/or postoperative drain reinfusion devices on allogeneic erythrocyte use was evaluated using a restrictive transfusion threshold. Methods: In a factorial design, adult elective hip- and knee-surgery patients with hemoglobin levels 10 to 13 g/dl (n = 683) were randomized for erythropoietin or not, and subsequently for autologous reinfusion by cell saver or postoperative drain reinfusion devices or for no blood salvage device. Primary outcomes were mean allogeneic intra- and postoperative erythrocyte use and proportion of transfused patients (transfusion rate). Secondary outcome was cost-effectiveness. Results: With erythropoietin (n = 339), mean erythrocyte use was 0.50 units (U)/patient and transfusion rate 16% while without (n = 344), these were 0.71 U/patient and 26%, respectively. Consequently, erythropoietin resulted in a nonsignificant 29% mean erythrocyte reduction (ratio, 0.71; 95% CI, 0.42 to 1.13) and 50% reduction of transfused patients (odds ratio, 0.5; 95% CI, 0.35 to 0.75). Erythropoietin increased costs by €785 per patient (95% CI, 262 to 1,309), that is, €7,300 per avoided transfusion (95% CI, 1,900 to 24,000). With autologous reinfusion, mean erythrocyte use was 0.65 U/patient and transfusion rate was 19% with erythropoietin (n = 214) and 0.76 U/patient and 29% without (n = 206). Compared with controls, autologous blood reinfusion did not result in erythrocyte reduction and increased costs by €537 per patient (95% CI, 45 to 1,030). Conclusions: In hip- and knee-replacement patients (hemoglobin level, 10 to 13 g/dl), even with a restrictive transfusion trigger, erythropoietin significantly avoids transfusion, however, at unacceptably high costs. Autologous blood salvage devices were not effective.

2014 ◽  
Vol 120 (4) ◽  
pp. 852-860 ◽  
Author(s):  
Cynthia So-Osman ◽  
Rob G. H. H. Nelissen ◽  
Ankie W. M. M. Koopman-van Gemert ◽  
Ewoud Kluyver ◽  
Ruud G. Pöll ◽  
...  

Abstract Background: Patient blood management is introduced as a new concept that involves the combined use of transfusion alternatives. In elective adult total hip- or knee-replacement surgery patients, the authors conducted a large randomized study on the integrated use of erythropoietin, cell saver, and/or postoperative drain reinfusion devices (DRAIN) to evaluate allogeneic erythrocyte use, while applying a restrictive transfusion threshold. Patients with a preoperative hemoglobin level greater than 13 g/dl were ineligible for erythropoietin and evaluated for the effect of autologous blood reinfusion. Methods: Patients were randomized between autologous reinfusion by cell saver or DRAIN or no blood salvage device. Primary outcomes were mean intra- and postoperative erythrocyte use and proportion of transfused patients (transfusion rate). Secondary outcome was cost-effectiveness. Results: In 1,759 evaluated total hip- and knee-replacement surgery patients, the mean erythrocyte use was 0.19 (SD, 0.9) erythrocyte units/patient in the autologous group (n = 1,061) and 0.22 (0.9) erythrocyte units/patient in the control group (n = 698) (P = 0.64). The transfusion rate was 7.7% in the autologous group compared with 8.3% in the control group (P = 0.19). No difference in erythrocyte use was found between cell saver and DRAIN groups. Costs were increased by €298 per patient (95% CI, 76 to 520). Conclusion: In patients with preoperative hemoglobin levels greater than 13 g/dl, autologous intra- and postoperative blood salvage devices were not effective as transfusion alternatives: use of these devices did not reduce erythrocyte use and increased costs.


2021 ◽  
Vol 10 (10) ◽  
pp. 2141
Author(s):  
Aimilia Tsante ◽  
Anastasia Papandreadi ◽  
Andreas G. Tsantes ◽  
Elias Kyriakou ◽  
Panagiota Douramani ◽  
...  

Objectives: Our aim was to assess blood utilization after implementation of a patient blood management (PBM) program in a Greek tertiary hospital. Methods: An electronic transfusion request form and a prospective audit of transfusion practice were implemented. After the one-year implementation period, a retrospective review was performed to assess transfusion practice in medical patients. Results: Pre-PBM, a total of 9478 RBC units were transfused (mean: 1.75 units per patient) compared with 9289 transfused units (mean: 1.57 units per patient) post-PBM. Regarding the post-PBM period, the mean hemoglobin (Hb) level of the 3099 medical patients without comorbidities transfused was 7.19 ± 0.79 gr/dL. Among them, 2065 (66.6%) had Hb levels >7.0 gr/dL, while 167 (5.3%) had Hb levels >8.0 gr/dL. In addition, 331 (25.3%) of the transfused patients with comorbidities had Hb >8.0 gr/dL. The Hb transfusion thresholds significantly differed across the clinics (p < 0.001), while 21.8% of all medical non-bleeding patients received more than one RBC unit transfusion. Conclusion: A poor adherence with the restrictive transfusion threshold of 7.0 gr/dL was observed. The adoption of a less strict threshold might be a temporary step to allow physicians to become familiar with the program and be informed on the safety and advantages of the restrictive transfusion strategy.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5081-5081
Author(s):  
Ana Belén Ortega López ◽  
Estefanía Morente Constantin ◽  
Pablo Romero Garcia ◽  
Maria Almudena Garcia Ruiz ◽  
Encarnación Moreno Abril ◽  
...  

Abstract INTRODUCTION Allogeneic red blood cell (RBC) transfusions are vital and effective and effective to treat anemia. RBC transfusions increase hospitalizations in 2.5 days, risk of death in 1.7 times and risk of infection in 1.9 times. The cost of discharges from the hospital is 1.83 times higher and it represents 7.8% of the hospitalization total expenses. However, there is little awareness and knowledge about this transfusion practice, as well as an inexplicable and enormous inter-center variability. In attempt to reduce unnecessary transfusions and improve postoperative evolution, as well as to reduce hospital costs, "Patient Blood Management" (PBM) program has been developed, which includes hospital policies, procedures and protocols. In literature, evidence of PBM programs effectiveness is growing. METHOD In view of the need to evaluate these issues, the Maturity Assessment Patient Blood Management (MAPBM) project was constituted in 2014, which involves a group of clinical and management experts nationwide, with the participation of 35 Spanish hospitals (including our center since 2015). It evaluates and compares:The knowledge of professionals about transfusion practice and PBM programs (anonymous survey). Figure 1.The PBM process indicators of each participating center. Figure 2.Inter-transfusion variability and factors related to transfusion in different procedures adjusted by age, sex and comorbidity. Figure 3 We will analyze the results of our center comparing them with the rest of hospitals. RESULTS In general, there is a high awareness of the indication and minimization of transfusions in different procedures, as well as a dissemination of our PBM programs above the average, especially the protocol of preoperative anemia (Figure 1). Despite this, the results of our circuit for the correction of preoperative anemia are unfavorable, since they are detected in a higher percentage than the rest of the centers, but they are not effectively treated in the studied procedures (Figure 2). Our strategies to minimize bleeding, both spinal anesthesia in orthopedic and traumatological surgeries and perioperative use of tranexamic acid are noteworthy, except in the cases of hip fracture surgeries, where its use was contraindicated by multidisciplinary consensus. Our transfusion threshold is close to the standard. In all the studied procedures, transfusion with Hb ≥ 8gr / dl is not considered. Regarding the results of transfusion and factors related to transfusion (Figure 3), a globally superior transfusion rate is observed, mainly at the expense of cardiac and open colorectal surgery. Regarding other items, our mortality and complications rates are, in general, unfavorable. However, hospitalizations and readmissions are lower. CONCLUSIONS Although the dissemination of our PBM strategies is adequate, its implementation has not meant an improvement in the transfusion rate of the procedures studied, being even higher than the expected rate. We assume that the lack of efficacy of the circuit for the correction of preoperative anemia is due to the intrinsic obstacles of our center. Among them:Premature programming in some patients, especially the case of cardiovascular surgery, which determines that the time between the surgical indication and the preoperative visit, is very limited.Lack of adequacy of the treatment at the date of intervention caused by lack of knowledge, especially in general surgery.The rigid criteria for the delivery of carboxymaltose iron limit the inclusion of patients who are closer to the intervention date, or determine an insufficient dosage of iron sucrose.Lack of diffusion of our program to different services when correcting postoperative anemia with iron. Strategies will be established by the Transfusion commission to solve the problems identified. As for the unfavorable results on transfusion practice (transfusion index, mortality and complications), it is essential to introduce improvements and update the optimal use of blood products by our professionals. This contradicts the results of the Transfusion Practice Survey. Therefore, we will take this data with caution, insisting on the awareness of adequate transfusion policies and PBM strategies, with the support of the hospital's management, and the dissemination of knowledge about these programs to achieve the commitment of the professionals involved. Disclosures No relevant conflicts of interest to declare.


Vox Sanguinis ◽  
2017 ◽  
Vol 112 (6) ◽  
pp. 499-510 ◽  
Author(s):  
R. A. Sikorski ◽  
N. A. Rizkalla ◽  
W. W. Yang ◽  
S. M. Frank

Cureus ◽  
2019 ◽  
Author(s):  
Alejandro Perez ◽  
Sara Bakhtary ◽  
Elena Nedelcu ◽  
Solmaz Manuel

2020 ◽  
Vol 9 (6) ◽  
pp. 1952
Author(s):  
Hanna Pérez-Chrzanowska ◽  
Norma G. Padilla-Eguiluz ◽  
Enrique Gómez-Barrena

The application of patient blood management (PBM) combined with tranexamic acid administration (TXA) results in decreased total blood loss volume (TVB) and transfusions in total hip replacements (THRs). Dosages, timing, and routes of administration of TXA are still under debate as all these aspects, as well as interpatient variations, may affect the efficacy of the protocol. This study aims to examine the effectiveness of timing and route of administration of TXA in combination with PBM by reducing the TBV following THR surgery. Consecutive primary uncemented THRs operated by a single surgical and anaesthetic team had the data prospectively collected and then retrospectively studied. Five treatment groups were formed, reflecting the progressive evolution of our protocol. Group 1 included patients managed with PBM alone (preoperative erythrocyte mass optimisation to at least 14 g/dL haemoglobin (Hb), hypotensive spinal anaesthesia and restrictive red blood cell transfusion criteria). Group 2 included patients with PBM and topical 3 g TXA diluted in normal saline to a total volume of 50 mL. Group 3 were patients with PBM and an IV dose of 20 mg/kg TXA at induction, followed by 20 mg/kg TXA as a continuous infusion for the duration of the operation. Group 4 consisted of patients managed as per Group 3 plus another 20 mg/kg TXA at three-hour post-procedure. Group 5 (combined): PBM and IV TXA as per Group 4 and topical TXA as per Group 2. A generalised linear model with the treatment group as an independent variable was modelled, using TBV as the dependent variable. The transfusion rate for all groups was 0%. TBV at 24 h, oscillated from 613.5 ± 337.63 mL in Group 1 to 376.29 ± 135.0 mL in Group 5. TBV at 48 h oscillated from 738.3 ± 367.3 mL (PBM group) to 434 ± 155.2 mL (PBM + combined group). The multivariate regression model confirmed a significant decrease of TBV in all groups with TXA compared with the PBM-only group. Overweight and preoperative Hb were confirmed to significantly influence TBV. The optimal regime to achieve the least TBV and a transfusion rate of 0% requires PBM and one loading 20 mg/kg dose of TXA, followed by continuous infusion of 20 mg/kg for the duration of the operation in uncemented THRs. Additional doses of TXA did not add a clear benefit.


Sign in / Sign up

Export Citation Format

Share Document